ONCAlert | 2017 San Antonio Breast Cancer Symposium
Colorectal Cancer Case Studies

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

Tanios Bekaii-Saab, MD
Published Online:Apr 26, 2016
Case 2 examines a 52-year-old woman newly diagnosed with metastatic CRC who is genotyped as part of her initial work up.

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2


For which mutations should patients diagnosed with metastatic CRC be tested?

The typical testing a few years ago was KRAS. That actually is now only part of the testing we should do for patients with metastatic colorectal cancer. Today, every patient should have an all RAS analysis, which includes KRAS and NRAS. The question of whether you add a BRAF analysis to that or not, it should not be routine, but I would suggest that it would be routine when you have capability to do it at your institution. BRAF would not inform you about EGFR, per se, but BRAF may lead you down a therapeutic path with, for example, triplet chemotherapy rather than a doublet chemotherapy plus bevacizumab.

I would say KRAS, NRAS, and whenever possible, BRAF, would be very informative in trying to help you make decisions, or the right decision for the patients.

Unresectable Colon Cancer: Case 2

52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.

Publications
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.